TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
Employ cutting-edge technology to discover and deliver high quality innovative biologics at affordable price to patients around the world.
We are a group of people with passion and experience for developing innovative medicines to serve patients around the world. We operate globally and focus on biologics, and we have established a fully integrated capability with a Discovery, Translational and Clinical Research Center in Suzhou, a Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Shanghai, Beijing and Princeton, US, and an External Partnering Center in Boston, US.
Co-founder & CEO
EVP, Head of Global R&D and CMO
Chief Technology Officer
Chief Operating Officer
EVP, Global Process & Product Development
SVP, Finance & Business Operations
SVP, Research
SVP, DMPK & Translational Science
SVP, Global Clinical Development
SVP, Global Clinical Development
SVP, Manufacturing
VP Commercial Planning and Business Development
Transcenta is backed by prominent investors with approximately $342 million, including Lilly Asia Ventures, Temasek, ARCH Venture Partners, China Structural Reform Fund, Teng Yue Partners, Hillhouse Capital, Sequoia Capital China, Taikang, China Merchants Capital, Country Garden Venture Capital, CRCP, Fortune Capital, Epiphron Capital, Qatar Investment Authority, KingStar Capital, China Equity Group and China Capital, etc. We appreciate their trust and support.
SVP Finance Business Operations
Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting. In addition, he also participated in a number of M&A consulting projects to assist domestic and foreign clients to carry out due diligence, design trading structure, to ensure smooth transactions, as well as to carry out the integration of the financial sector to improve the clients and the target companies’ financial system and processes. Albert has received his bachelor degree from Sun Yat-sen University and is a member of the CICPA and the ACCA.
